Observational studyScientific reports2026
Risk of stroke following SARS-CoV-2 infection in a nationwide self-controlled case series study in qatar.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study investigated stroke incidence after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection using Qatar’s nationwide stroke registry linked with national testing, vaccination, and mortality databases. A self-controlled case series design was implemented among individuals with stroke and confirmed primary SARS-CoV-2 infection between January 1, 2020, and April 11, 2023. Incidence rate ratios (IRRs) comparing stroke incidence rate during the 1–90 days post-infection with predefined control periods were estimated using conditional Poisson regression. Of 4,187 stroke cases, 338 with confirmed infection met inclusion criteria. Stroke incidence rate was elevated during the 1–90 days post-infection (IRR 1.84, 95% CI: 1.31–2.58), peaking at days 1–28 (IRR 2.22, 95% CI: 1.53–3.22) and declining thereafter (days 29–59: IRR 1.47, 95% CI: 0.97–2.24; days 60–90: IRR 0.72, 95% CI: 0.43–1.21). This corresponded to 5.9 excess strokes per 100,000 infections. Elevated risk was confined to pre-Omicron infections (IRR 2.98, 95% CI: 1.89–4.70), with no evidence of increased risk observed for Omicron infections (IRR 0.82, 95% CI: 0.46–1.45). Subtype analyses showed increased risk for ischemic stroke (IRR 1.99, 95% CI: 1.37–2.89) and cerebral venous sinus thrombosis (CVST; IRR 3.52, 95% CI: 1.15–10.78), but not hemorrhagic stroke (IRR 0.64, 95% CI: 0.16–2.51). SARS-CoV-2 infection was associated with a transient elevation in stroke risk, peaking shortly after infection and declining thereafter. Excess risk was confined to pre-Omicron infections and driven primarily by ischemic stroke, while CVST, though rare, showed the strongest relative effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.